Concepedia

Anders Björk

AB

9

Publications

1.1K

Citations

9

H-Index

1989

Active since

Affiliations

Active Biotech (Sweden)(Current)

Lund University

Johns Hopkins University

Sidney Kimmel Comprehensive Cancer Center

Anders Björk is an author at Active Biotech (Sweden) specializing in medicine, pharmacology, and psychopharmacology.

Top concepts

Publications per year

1989–2011

9

Publications

9

Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

Per Björk, Anders Björk, Thomas Vogl et al. · PLoS Biology · 2009 · 352 citations · Full text

, , +20

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich et al. · Journal of Clinical Oncology · 2011 · 208 citations

Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship

Stig Jönsson, Gunnar Andersson, Tomas Fex et al. · Journal of Medicinal Chemistry · 2004 · 156 citations

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

Anders Olsson, Anders Björk, Johan Vallon‐Christersson et al. · Molecular Cancer · 2010 · 90 citations · Full text

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

John T. Isaacs, David Z. Qian, Susan L. Dalrymple et al. · The Prostate · 2006 · 87 citations

Rows per page

1–5 of 9